Total raised
—
Last: Undisclosed 2017-05
Stage
Seed
Founded
2016
Headcount
1-10
HQ
Ness Ziona
Sector
Health Tech & Life Sciences
About
XL Therapeutics is a biopharmaceutical company aiming to develop small molecule compounds to treat patients suffering from Wiskott-Aldrich syndrome (WAS) and X-linked thrombocytopenia, rare primary human immunodeficiencies caused by the absence or suboptimal function of the WAS protein (WASp), an adaptor protein expressed exclusively in hematopoietic cells and essential for normal hematopoietic cell function.
Funding history · 1 round · — total
2017-05
Undisclosed
Undisclosed
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- What is the primary focus of XL Therapeutics?
- XL Therapeutics is a biopharmaceutical company focused on developing small molecule compounds to treat Wiskott-Aldrich syndrome (WAS) and X-linked thrombocytopenia.
- When was XL Therapeutics founded?
- XL Therapeutics was founded in May 2016.
- What is the current operational status of XL Therapeutics?
- XL Therapeutics is currently inactive and ceased operations in May 2019.
- Where is XL Therapeutics headquartered?
- XL Therapeutics is headquartered in Ness Ziona, Israel.
- Which investors participated in XL Therapeutics' funding rounds?
- In May 2017, XL Therapeutics received an Undisclosed round of funding with FutuRx as an investor.
- What is the employee count for XL Therapeutics?
- XL Therapeutics has an employee count in the range of 1-10.
- Who are the founders of XL Therapeutics?
- The founders of XL Therapeutics are Rachel Eran and Mira Barda-Saad.
- What is the product stage of XL Therapeutics?
- The product stage of XL Therapeutics is clinical trial.
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
Biologicals
Target customers
Healthcare & Life SciencesHealthcareProvidersPatientsLife SciencesPharmaceuticals
Business model
B2B
Tags
medical-technologiesvascularpatientshospitalspharmaceuticalstreatments